[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Ashman JB, Connell PP, Yamada D, Rotmensch J, Waggoner SE, Mundt AJ: Outcome of endometrial carcinoma patients with involvement of the uterine serosa. Gynecol Oncol; 2001 Aug;82(2):338-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of endometrial carcinoma patients with involvement of the uterine serosa.
  • OBJECTIVE: The goal of this work was to evaluate the outcome of endometrial carcinoma patients undergoing primary surgery who have serosal involvement (SI).
  • METHODS: Between 1980 and 1998, 562 women underwent primary surgery for endometrial cancer at the University of Chicago.
  • FIGO stages were IIIA (19), IIIB (1), IIIC (7), and IV (12).
  • Of the 19 IIIA patients, 15 had solitary SI.
  • Twenty-six patients received pelvic radiation therapy (RT) with or without vaginal brachytherapy (VB).
  • One patient received whole-abdomen radiation therapy, and 13, adjuvant chemotherapy.
  • Solitary SI patients received pelvic RT with or without VB as their sole adjuvant therapy.
  • RESULTS: With a median follow-up of 30.3 months, the 5-year actuarial DFS of the entire group was 28.9%.
  • Factors correlated with disease recurrence included tumor stage (P = 0.003) and lymph node involvement (P = 0.04).
  • CONCLUSION: Endometrial carcinoma patients with SI have a high rate of relapse and a poor outcome.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11531290.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / 5 T32 GM07281
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


2. Eltabbakh GH, Mount SL: Laparoscopic surgery does not increase the positive peritoneal cytology among women with endometrial carcinoma. Gynecol Oncol; 2006 Feb;100(2):361-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic surgery does not increase the positive peritoneal cytology among women with endometrial carcinoma.
  • OBJECTIVE: The purpose of our study was to find if uterine manipulation at the time of laparoscopic hysterectomy among women with endometrial carcinoma increases the incidence of malignant cells in the peritoneal washings.
  • MATERIAL AND METHODS: We conducted a prospective study including women with clinical stage I endometrioid endometrial carcinoma undergoing laparoscopic surgery between 07/01/2000 and 07/01/2004.
  • Two sets of peritoneal washings were obtained, one before and one after the insertion of the Pelosi uterine manipulator.
  • The two sets of washings were blindly reviewed by the same cytopathologist for the presence of malignant cells.
  • The procedure was converted to laparotomy in 3 (7.6%) patients after obtaining the two sets of washings.
  • The preoperative tumor grades were: G1: 22 (52.4%), G2: 12 (28.6%), and G3: 8 (19.0).
  • No patients had positive washings after the insertion of the uterine manipulator if the washings were negative before the insertion.
  • The surgical stages were: IA: 14 (33.3%), IB: 12 (28.6%), IC: 7 (16.7%), IIA: 1 (2.4%), IIB: 1 (2.4%), IIIA: 4 (9.5%), IIIB: 1 (2.4%), IIIC: 1 (2.4%), and IV: 1 (2.4%).
  • Twenty-nine patients received no postoperative treatment, 2 received chemotherapy, 3 received Megace, and 9 received radiation therapy.
  • Two patients had tumor recurrence, and one patient died secondary to her disease.
  • CONCLUSIONS: We conclude that uterine manipulation at the time of laparoscopic hysterectomy does not increase the incidence of positive peritoneal cytology among women with endometrial carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Carcinoma, Endometrioid / surgery. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Neoplasm Seeding. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185754.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Havrilesky LJ, Cragun JM, Calingaert B, Alvarez Secord A, Valea FA, Clarke-Pearson DL, Berchuck A, Soper JT: The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer. Gynecol Oncol; 2007 Feb;104(2):401-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic significance of positive peritoneal cytology and adnexal/serosal metastasis in stage IIIA endometrial cancer.
  • OBJECTIVE: The clinical significance and optimal management of patients with stage IIIA endometrial cancer are controversial.
  • We sought to determine whether recurrence and survival of patients with stage IIIA endometrial cancer differ with surgical pathologic findings (positive peritoneal cytology versus positive adnexae or serosa) and adjuvant treatment.
  • METHODS: Retrospective single institution analysis of patients surgically staged for IIIA endometrial cancer at Duke University Medical Center from 1973 to 2002.
  • Stage IIIA patients were stratified into positive cytology alone (group IIIA1, n=37) and positive adnexae or uterine serosa (group IIIA2, n=20).
  • Comparison was made with previously reported group of 467 patients with surgical stage I/II disease.
  • RESULTS: Mean age of 57 patients with stage IIIA endometrial cancer was 63.
  • Adjuvant therapies were administered to 89% patients (74% radiotherapy, 4% chemotherapy, 19% progestins).
  • RFDSS by adjuvant therapy was: external beam radiotherapy 89% (n=10), intraperitoneal P32 84% (n=21), progestins 78% (n=9), none 75% (n=6).
  • In multivariable analysis of stage I-IIIA patients (n=517), positive cytology but not adnexal/serosal metastasis was predictive of death (HR 1.70, 95% CI 1.06-2.73) and disease recurrence (HR 1.70, 95% CI 1.07-2.71).
  • CONCLUSION: Among patients with stage IIIA endometrial cancer, metastasis to adnexae or serosa does not appear to confer worse prognosis than positive cytology alone.
  • Positive cytology is an independent predictor of prognosis among patients with stage I-IIIA endometrial cancer.
  • While optimal adjuvant therapy for these groups remains unclear, recurrence patterns suggest that systemic therapies are appropriate.
  • [MeSH-major] Adnexa Uteri / pathology. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / secondary. Ovarian Neoplasms / secondary. Peritoneal Cavity / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17014898.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Stanojevic Z, Djordjevic B, Todorovska I, Lilic V, Zivadinovic R, Dunjic O: Risk factors and adjuvant chemotherapy in the treatment of endometrial cancer. J BUON; 2008 Jan-Mar;13(1):23-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors and adjuvant chemotherapy in the treatment of endometrial cancer.
  • Endometrial carcinoma is the most common and potentially curable gynecologic malignant neoplasm.
  • The staging of endometrial cancer, according to the International Federation of Gynecology and Obstetrics (FIGO), is surgical.
  • Recent studies suggest a therapeutic benefit associated with extensive retroperitoneal lymph node evaluation to determine the disease extent and thereby more effectively direct potentially life-saving adjuvant therapy.
  • Due to the increasing number of endometrial cancer patients who undergo surgical staging, some independent prognostic factors have been identified in early stages (stage I-II), including lymph-vascular space involvement, histologic grade 3, aggressive histologic subtypes (uterine papillary serous carcinoma, clear cell carcinoma), depth of myometrial invasion, cervical invasion and the age of patients.
  • Adjuvant radiation therapy, known to offer survival benefit in advanced-stage disease, may also offer survival benefit in intermediate-risk surgical stage I, but this is followed by a significant risk of serious complications.
  • Based on randomized clinical trials, this review identified that only a limited body of evidence is available which can help clinicians make decisions about adjuvant chemotherapy of patients with high-risk stage I and II, as well as stage IIIA endometrial cancer.
  • Further investigations are required to define the subgroup of patients who benefit from postoperative adjuvant chemotherapy.
  • Thereby, combination of carboplatin plus paclitaxel represents an efficacious, low-toxicity regimen for managing intermediate-risk surgical stage I, as well as advanced or recurrent endometrial cancer.
  • [MeSH-major] Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / etiology
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Neoplasm Staging. Risk Factors

  • Genetic Alliance. consumer health - Endometrial cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404782.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Number-of-references] 66
  •  go-up   go-down


5. Hiura M, Nogawa T, Matsumoto T, Yokoyama T, Shiroyama Y, Wroblewski J: Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma. Int J Gynecol Cancer; 2010 Aug;20(6):1000-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
  • OBJECTIVE: The purposes of this study were to assess modified radical hysterectomy including systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy in patients with para-aortic lymph node (PAN) metastasis in endometrial carcinoma and to identify the multivariate independent prognostic factors for long-term survival during the past 10 years.
  • METHODS: Between December 1987 and December 2002, we performed modified radical hysterectomy with bilateral salpingo-oophorectomy including systematic pelvic and para-aortic lymphadenectomy and peritoneal cytology in 284 endometrial carcinoma patients according to the classification of the International Federation of Gynecology and Obstetrics (stage IA, n = 66; stage IB, n = 96; stage IC, n = 33; stage IIA, n = 5; stage IIB, n = 20; stage IIIA, n = 28; stage IIIC, n = 28; and stage IV, n = 8) who gave informed consents at our institute.
  • Patients with tumor confined to the uterus (stages IC and II) were treated by 3 courses of cyclophosphamide 750 mg/m2, epirubicin 50 mg/m2, and cisplatin 75 mg/m2 regimen 3 to 4 weeks apart, and patients with extrauterine lesions involving adnexa and/or pelvic lymph node (PLN) were treated by 5 courses.
  • Patients with PLN metastasis received adjuvant chemotherapy, and adjuvant radiation was not part of our institutional protocol.
  • RESULTS: The overall incidence of retroperitoneal lymph node metastasis assessed by systematic pelvic and para-aortic lymphadenectomy was 12.0% (34/284) in stages I to IV endometrial carcinoma, and incidences of PLN and PAN metastases were 9.2% (26/284) and 7.4% (21/284), respectively.
  • Univariate analysis of prognostic factors revealed that International Federation of Gynecology and Obstetrics clinical stage (P < 0.0001), histological finding (P = 0.0292), myometrial invasion (P < 0.0001), adnexal metastasis (P < 0.0001), lymphovascular space invasion (P < 0.0001), tumor diameter (P = 0.0108), peritoneal cytology (P = 0.0001), and retroperitoneal lymph node metastasis (P < 0.0001) were significantly associated with 10-year overall survival.
  • CONCLUSIONS: It is suggested that surgery with systematic pelvic and para-aortic lymphadenectomy followed by adjuvant chemotherapy could improve long-term survival in patients with PAN metastasis, although there are only 21 patients with PAN metastasis.
  • [MeSH-major] Carcinoma / mortality. Carcinoma / secondary. Chemotherapy, Adjuvant. Endometrial Neoplasms / mortality. Endometrial Neoplasms / therapy. Retroperitoneal Neoplasms / secondary. Retroperitoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Aorta, Abdominal. Biopsy, Needle. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Lymph Node Excision / methods. Lymph Nodes / pathology. Lymph Nodes / surgery. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Retroperitoneal Space. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683408.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Jewell E, Secord AA, Brotherton T, Berchuck A: Use of trastuzumab in the treatment of metastatic endometrial cancer. Int J Gynecol Cancer; 2006 May-Jun;16(3):1370-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of trastuzumab in the treatment of metastatic endometrial cancer.
  • Systemic therapy of metastatic endometrial cancer is relatively ineffective.
  • Response rates to chemotherapy and hormonal therapy in published studies range from 11% to 57%, but most responses are partial and of limited duration.
  • In this case, we present a 76-year-old woman with stage IIIA endometrial adenocarcinoma who was initially treated with surgery and pelvic radiation.
  • She developed multiple pulmonary metastases.
  • She was treated with weekly paclitaxel chemotherapy.
  • Immunostaining revealed that the primary endometrial cancer overexpressed HER-2/neu.
  • After a second pulmonary relapse following discontinuation of prior therapy, she was again successfully treated with trastuzumab in combination with paclitaxel and then docetaxel.
  • Therefore, trastuzumab may be a useful adjuvant to taxane-based chemotherapy in some patients with metastatic endometrial cancers that overexpress HER-2/neu.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / therapeutic use. Endometrial Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Paclitaxel / administration & dosage. Receptor, ErbB-2 / metabolism. Taxoids / administration & dosage. Trastuzumab

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803532.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Taxoids; 15H5577CQD / docetaxel; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


7. Gocheva L, Slavchev B: Whole abdominal irradiation in endometrial cancer - a single institution study. J BUON; 2009 Oct-Dec;14(4):613-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole abdominal irradiation in endometrial cancer - a single institution study.
  • PURPOSE: To examine the use of whole abdominal irradiation (WAI) open field technique in patients with stage III endometrial cancer (EC).
  • METHODS: Between 1993 and 2007, 26 patients (age 39-70 years, median 58) with stage III EC (IIIA 15, IIIB 2, IIIC 8) were treated with WAI after primary surgery.
  • In 84% of the patients WAI consisted of 30 Gy, delivered mainly in daily fractions of 1.5 Gy (81%), 5 fractions per week.
  • For the remaining patients the dose was 25 Gy (8%) and 20 Gy (8%), respectively.
  • After abdominal RT, 85% of the patients were given a pelvic boost to reach 45 - 50 Gy with 1.8 Gy/fraction/day, using a Co 60 unit.
  • In 5 (19%) patients boost to 45-50 Gy with 1.8 Gy/fraction/day to other risk sites was also given.
  • Two (8%) of 26 patients received 2 cycles of platinum-based chemotherapy.
  • The mean follow-up time was 13.41 years.
  • RESULTS: The treatment time ranged from 14-74 days, median 48.
  • Ten (38.5%) patients received their treatment with no interruption, and in 16 (61.5%) patients RT was transiently interrupted because of acute gastrointestinal and hematological toxicity.
  • Neither grade 4 acute complications nor mortality while receiving treatment were observed.
  • Late side effects (grade 2 gastrointestinal complications) developed in 1 (5%) patient.
  • CONCLUSION: WAI achieves a quite favorable 5- and 14-year survival rate with an acceptable risk of acute and late side effects in properly selected patients with stage III EC.
  • WAI as a sole or a part of combined treatment warrants further investigation in patients with high-risk EC.
  • [MeSH-major] Abdomen / radiation effects. Adenocarcinoma / radiotherapy. Endometrial Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148451.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


8. Eltabbakh GH, Shamonki J, Mount SL: Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumors. Gynecol Oncol; 2005 Nov;99(2):309-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumors.
  • OBJECTIVE: The purpose of our study was to assess the surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy showed well-differentiated (FIGO grade 1) carcinoma.
  • MATERIALS AND METHODS: A retrospective study was conducted including all women treated at the University of Vermont between 1992 and 2004 whose preoperative endometrial biopsy was reviewed by the staff at the Pathology Department and diagnosed as FIGO grade 1 adenocarcinoma and who received peritoneal washings, total abdominal (or laparoscopic) hysterectomy, bilateral salpingo-oophorectomy, and pelvic +/- para-aortic lymphadenectomy as part of their surgery.
  • The surgical stages were: IA: 55 (30.2%), IB: 61 (33.5%), IC: 26 (14.3%), IIA: 9 (4.9%), IIB: 8 (4.4%), IIIA: 10 (5.5%), IIIB: 2 (1.1%), IIIC: 8 (4.4%), and IV: 3 (1.6%).
  • Postoperatively, 131 (72%) patients received no additional treatment, 47 (25.8%) received radiation therapy, 3 (1.6%) received chemotherapy, and 1 (0.5%) received Megace.
  • CONCLUSIONS: Approximately 30% of women with endometrial carcinoma whose preoperative endometrial biopsy shows grade 1 tumors have grade 2 or 3 in the hysterectomy specimen and 12.6% have advanced surgical stage (stage III and IV) disease.
  • Women with preoperative endometrial biopsy showing grade 1 tumors who undergo surgical staging have excellent survival and acceptable operative morbidity.
  • [MeSH-major] Endometrial Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Aged, 80 and over. Biopsy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / surgery. Cell Differentiation / physiology. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16005945.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Havrilesky LJ, Secord AA, O'Malley DM, Broadwater G, Bae-Jump V, Cohn DE, Gehrig PA: Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer. Gynecol Oncol; 2009 Aug;114(2):279-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicenter analysis of recurrence and survival in stage IIIA endometrial cancer.
  • OBJECTIVE: To determine factors related to recurrence and survival in women with stage IIIA endometrial cancer; to examine outcomes of women with IIIA1 disease.
  • METHODS: Multi-institutional analysis of women with stage IIIA endometrial carcinoma undergoing hysterectomy, bilateral salpingo-oophorectomy, lymphadenectomy, and pelvic cytology between 1980 and 2008.
  • RESULTS: 98 women underwent surgical staging for stage IIIA endometrial carcinoma.
  • Adjuvant treatment was given to 88%: radiotherapy--21%, chemotherapy - 19%, chemotherapy and radiotherapy--19%, hormonal therapy--16%, and intraperitoneal P-32 - 11%.
  • Patients with IIIA1 disease were less likely to receive chemotherapy or radiotherapy than those with IIIA2 disease (p=0.0035).
  • Older age (Hazard ratio 1.24; 95% CI 1.00-1.54), non-Caucasian race (HR 5.35; 95% CI 1.96-14.5), and cervical metastases (HR 3.3; 95% CI 1.3-8.7) predicted lower RFDSS in multivariate analysis.
  • Among 24 patients meeting NCCN's observation criteria (IIIA1, non-serous, and FIGO grade 1-2), 0/12 receiving adjuvant treatment recurred, while 1/12 not receiving adjuvant treatment recurred.
  • CONCLUSIONS: Surgically assessed stage IIIA endometrial adenocarcinoma recurs in approximately 20-25% of cases.
  • A subset of stage IIIA1 with very low risk factors may be appropriate candidates for observation.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Hysterectomy. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Ovariectomy. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19446319.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Djurdjević S, Mladenović-Segedi L, Djolai M: Endometrical cancer metastases in the region of abdominal muscles and pelvic wall. J BUON; 2006 Jan-Mar;11(1):75-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrical cancer metastases in the region of abdominal muscles and pelvic wall.
  • We present a case of surgical removal of solitary metastases in the region of anterior and lateral pelvic wall following primary surgery, pelvic irradiation (external beam-Linac X 6 MV to whole pelvis, followed by intra-vaginal Ir(192)), and adjuvant chemotherapy (carboplatin/adriamycin) in a patient with endometrial adenocarcinoma, FIGO stage IIIA, performed on 3 consecutive recurrences.
  • The first of them was in the region of m.
  • [MeSH-major] Abdominal Muscles / pathology. Abdominal Neoplasms / secondary. Adenocarcinoma / secondary. Endometrial Neoplasms / pathology. Pelvic Neoplasms / secondary
  • [MeSH-minor] Female. Humans. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318956.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


11. Dusenbery KE, Potish RA, Gold DG, Boente MP: Utility and limitations of abdominal radiotherapy in the management of endometrial carcinomas. Gynecol Oncol; 2005 Mar;96(3):635-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility and limitations of abdominal radiotherapy in the management of endometrial carcinomas.
  • OBJECTIVE: The present review analyzes long-term survival, recurrence sites, and toxicity in women with peritoneal spread of endometrial treated with abdominal radiotherapy, in order to provide therapeutic options as a function of disease spread and histology.
  • METHODS: Retrospective medical record review was performed of 86 patients receiving abdominal radiotherapy for endometrial carcinomas from 1975 to 1995 at the University of Minnesota.
  • RESULTS: FIGO stage distribution was 54 stage IIIA, 2 stage IIIB, 11 stage IIIC, and 19 stage IVB.
  • Recurrence rates were 16% for stage IIIA with one peritoneal site, 48% for stage IIIA with multiple peritoneal sites or stage IIIB or stage IIIC, and 72% for stage IVB.
  • With univariate analysis, statistical significance was found for stage, gross peritoneal disease, nodal metastases, histology, concurrent chemotherapy, isolated adnexal spread, grade, angiolymphatic invasion, myometrial invasion, and age.
  • Multivariate analysis found only stage, histology, and age to be significant.
  • CONCLUSIONS: Abdominal radiotherapy confers an excellent prognosis for women with stage IIIA cancers with one site of peritoneal involvement.
  • Lack of randomized trials makes definitive treatment recommendations difficult to provide.
  • [MeSH-major] Endometrial Neoplasms / pathology. Endometrial Neoplasms / radiotherapy. Peritoneal Neoplasms / radiotherapy. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma, Clear Cell / pathology. Adenocarcinoma, Clear Cell / radiotherapy. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / radiotherapy. Adenocarcinoma, Papillary / secondary. Adult. Aged. Aged, 80 and over. Cohort Studies. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / radiotherapy. Cystadenocarcinoma, Serous / secondary. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Radiotherapy / adverse effects. Radiotherapy / methods. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721405.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Murphy KT, Rotmensch J, Yamada SD, Mundt AJ: Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys; 2003 Apr 1;55(5):1272-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.
  • PURPOSE: To evaluate the outcome and patterns of failure in women with uterine clear-cell carcinoma and discuss implications for adjuvant radiation therapy (RT).
  • METHODS: Between 1980 and 2000, 686 endometrial carcinoma patients underwent primary surgery at our institution.
  • Thirty-eight women (5.5%) had clear-cell tumors (18 clear-cell only, 8 clear-cell + adenocarcinoma, and 12 clear-cell + other unfavorable histologies [10 papillary serous, 1 uterine sarcoma, 1 both]).
  • FIGO stages were as follows: 3 IA, 4 IB, 5 IC, 4 IIA, 6 IIB, 8 IIIA, 2 IIIB, 3 IIIC, and 6 IV.
  • Adjuvant therapies included the following: 5 none, 22 RT (13 pelvic RT, 2 vaginal brachytherapy, 7 both), 11 chemotherapy (8 alone, 3 after pelvic RT), and 3 hormones.
  • No correlation was seen between relapse and stage, myometrial invasion, cytology, cervical extension, or involvement of extrauterine sites.
  • Corresponding pelvic failure rates in the Stage IA-IIB patients with and without RT were 0/16 (0%) and 5/6 (83%) (p < 0.0001).
  • Only 1 (2%) patient developed an isolated abdominal failure (This patient had a mixed clear-cell/papillary serous tumor).
  • CONCLUSION: Clear-cell carcinoma comprises a small percentage of endometrial cancers, frequently presents as a mixed histology, and has a poor overall outcome.
  • Unlike papillary serous tumors, clear-cell carcinoma does not seem to have a high propensity for abdominal failure.
  • Future protocols should focus instead on combinations of locoregional RT and chemotherapy to reduce the risk of local and systemic recurrence.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometrial Neoplasms / pathology. Radiotherapy, Adjuvant
  • [MeSH-minor] Abdominal Neoplasms / secondary. Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Brachytherapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Cystadenocarcinoma / pathology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy. Life Tables. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / mortality. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Multiple Primary / surgery. Pelvic Neoplasms / secondary. Prognosis. Sarcoma / pathology. Treatment Failure. Treatment Outcome. Uterine Neoplasms / pathology. Vaginal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12654437.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 30
  •  go-up   go-down


13. Kuoppala T, Mäenpää J, Tomas E, Puistola U, Salmi T, Grenman S, Lehtovirta P, Fors M, Luukkaala T, Sipilä P: Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. Gynecol Oncol; 2008 Aug;110(2):190-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy.
  • OBJECTIVE: Our purpose was to establish whether platinum-based chemotherapy combined with standard surgery and radiotherapy will improve overall and disease-free survival and lower the recurrence rate in patients with high-risk endometrial cancer.
  • STUDY DESIGN: A total of 156 patients with Stage IA-B Grade 3 (n=28), or Stage IC-IIIA Grade 1-3 (n=128) were postoperatively randomized to receive radiotherapy (56 Gy) only (Group A, n=72) or radiotherapy combined with three courses of cisplatin (50 mg/m(2)), epirubicin (60 mg/m(2)) and cyclophosphamide (500 mg/m(2)) (Group B, n=84).
  • As calculated from the operation, the median time to recurrence was 15 (range 6-37) months in Group A, and 20 (range 8-60) months in Group B, respectively (p=0.170).
  • Chemotherapy was associated with an acceptable rate of acute toxicity.
  • A total of 10 patients developed intestinal complications demanding surgery, 2 in Group A (2.7%) and 8 (9.5%) in Group B, respectively.
  • CONCLUSION: Adjuvant chemotherapy with cisplatin, epirubicin and cyclophosphamide failed to improve overall survival or lower the recurrence rate in patients operated on and radiated for high-risk endometrial carcinoma.
  • Chemotherapy was associated with a low rate of acute toxicity but appeared to increase the risk of bowel complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, Adjuvant / adverse effects. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18534669.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Wong FC, Pang CP, Tang SK, Tung SY, Leung TW, Sze WK, Cheung KB: Treatment results of endometrial carcinoma with positive peritoneal washing, adnexal involvement and serosal involvement. Clin Oncol (R Coll Radiol); 2004 Aug;16(5):350-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results of endometrial carcinoma with positive peritoneal washing, adnexal involvement and serosal involvement.
  • AIMS: To review the treatment results of patients with endometrial carcinoma having positive peritoneal washing (PPW), adnexal involvement, uterine serosal involvement, or all three.
  • MATERIALS AND METHODS: The treatment records of patients who had undergone primary surgery for endometrial cancer without distant metastasis during 1990--2001 at the Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, were reviewed.
  • Thirty-five patients were found to have involvement of positive PPW, adnexal involvement, uterine serosal involvement, or all three.
  • Two patients with solitary ovarian metastasis received chemotherapy, and one with isolated PPW also received adjuvant hormonal therapy.
  • RESULTS: Among the 28 patients with clinical or pathological node-negative disease (International Federation of Gynecology and Obstetrics [FIGO] stage IIIA), only two patients with solitary ovarian metastases developed recurrence.
  • Five out of the seven patients with lymph-node involvement developed recurrences.
  • Only one patient (3.7%) who had received WART developed grade 4 toxicity.
  • CONCLUSIONS: This study showed that good treatment results could be obtained from patients with stage IIIA endometrial carcinoma without clinical or pathological lymph-node involvement after adjuvant radiotherapy, with acceptable late side-effects.
  • The relative prognostic importance of individual IIIA involvement and the optimal adjuvant treatment remain to be determined.
  • [MeSH-major] Ascitic Fluid / pathology. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Middle Aged. Multivariate Analysis. Myometrium / pathology. Neoplasm Staging. Ovary / pathology. Prognosis. Proportional Hazards Models. Radiotherapy, Adjuvant. Review Literature as Topic. Risk Factors. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15341439.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Frigerio L, Mangili G, Aletti G, Carnelli M, Garavaglia E, Beatrice S, Ferrari A: Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study. Gynecol Oncol; 2001 Apr;81(1):53-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study.
  • OBJECTIVE: Postoperative radiotherapy (RT) is the most used adjuvant treatment in high risk endometrial cancer (HREC), and it appears to reduce the incidence of pelvic relapses but doesn't seem to improve survival.
  • Paclitaxel (P) has shown in vitro and clinical activity against endometrial cancer, and it is also a potent radiosensitizer by blocking dividing cells in G2/M phase.
  • This is the first study that verifies the feasibility of a treatment with concomitant weekly chemotherapy and RT to potentially reduce the incidence of local and distant relapses in order to improve survival in HREC.
  • Four patients presented stage IC disease, 2 women had IIB stage tumors, 5 patients revealed IIIA stage disease, and 2 had stage IIIC.
  • /m(2)) via a continuous 1-h infusion once weekly during the 5 weeks of RT (mean radiation dose of 50.4 Gy).
  • One patient developed a subocclusion 8 weeks after the end of the treatment, with medical resolution.
  • No patients developed hypersensitivity reactions.
  • CONCLUSIONS: Concomitant P and RT is safe and acceptable treatment in patients with HREC.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / radiotherapy. Paclitaxel / adverse effects. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Diarrhea / chemically induced. Diarrhea / etiology. Drug Administration Schedule. Drug Eruptions / etiology. Feasibility Studies. Female. Hematologic Diseases / chemically induced. Hematologic Diseases / etiology. Humans. Middle Aged. Neoplasm Staging. Radiation Injuries / etiology. Radiodermatitis / etiology. Radiotherapy / adverse effects. Radiotherapy, Adjuvant. Risk Factors

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11277649.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Radiation-Sensitizing Agents; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


16. Thomas L, Bataillard A, Brémond A, Fondrinier E, Fervers B, Achard JL, Lansac J, Bailly C, Hoffstetter S, Basuyau JP, d'Anjou J, Descamps P, Farsi F, Guastalla JP, Laffargue F, Rodier JF, Vincent P, Pigneux J: [Standards, options, and recommendations for the radiotherapy of patients with endometrial cancer. FNCLCC (National Federation of Cancer Campaign Centers) and CRLCC (Regional Cancer Campaign Centers)]. Cancer Radiother; 2001 Apr;5(2):163-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Standards, options, and recommendations for the radiotherapy of patients with endometrial cancer. FNCLCC (National Federation of Cancer Campaign Centers) and CRLCC (Regional Cancer Campaign Centers)].
  • [Transliterated title] Standards, Options et Recommandations pour la radiothérapie des patientes atteintes de cancer de l'endomètre.
  • OBJECTIVES: To develop clinical practice guidelines according to the definitions of the Standards, Options and Recommendations project for the radiotherapy of carcinoma of the endometrium.
  • Once the guidelines were defined, the document was submitted for review to independent reviewers, and to the medical committees of the 20 French Cancer Centres.
  • RESULTS: The main recommendations for the radiotherapy of carcinoma of the endometrium are:.
  • 1) For grade 1 and 2 stage IA tumours, follow-up alone is standard as additional treatment.
  • For grade 1 and 2 stage IB tumours, vaginal brachytherapy or follow-up alone are options.
  • For grade 3, stage IB tumours and stage IC disease, there are two treatment options: external pelvic radiotherapy with a brachytherapy boost or vaginal brachytherapy.
  • 2) Treatment for stage II disease can be preoperative when stage II disease has been suggested by a positive endometrial curettage.
  • Postoperative vaginal brachytherapy is given for stage IIA tumours if the penetration of the myometrium is less than 50% or if the tumour is grade 1 or 2.
  • In the case of deep penetration, or higher grade disease, or for stage IIB external radiotherapy with brachytherapy boosting must be undertaken routinely.
  • 3) After surgery, for stage IIIA disease, either external pelvic radiotherapy or abdomino-pelvic radiotherapy is indicated, along with medical treatment in certain patients.
  • For stage IIIB tumours, postoperative external radiotherapy with brachytherapy (if possible) should be undertaken.
  • For stage IIIC tumours, standard treatment is external (pelvic or pelvic and para-aortic) radiotherapy followed or not by a brachytherapy boost.
  • In case of extrauterine sites involved abdomino-pelvic irradiation is recommended.
  • 4) Standard treatment for inoperable stage I and II disease is external radiotherapy and brachytherapy.
  • For patients with inoperable stage III or IV disease, treatment is often symptomatic, combining external radiotherapy and medical treatment.
  • [MeSH-major] Endometrial Neoplasms / radiotherapy. Radiotherapy / standards
  • [MeSH-minor] Brachytherapy / adverse effects. Carcinoma / drug therapy. Carcinoma / pathology. Carcinoma / radiotherapy. Carcinoma / surgery. Cesium Radioisotopes / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Hysterectomy. Indium Radioisotopes / therapeutic use. Lymphatic Irradiation / adverse effects. Lymphatic Metastasis / radiotherapy. Neoplasm Staging. Pelvic Neoplasms / radiotherapy. Pelvic Neoplasms / secondary. Peritoneal Neoplasms / radiotherapy. Peritoneal Neoplasms / secondary. Postoperative Period. Preoperative Care. Radiation Injuries / etiology. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, High-Energy / adverse effects. Radium / therapeutic use

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11355582.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Guideline; Journal Article; Practice Guideline; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Cesium Radioisotopes; 0 / Indium Radioisotopes; W90AYD6R3Q / Radium
  •  go-up   go-down


17. Lin O: Challenges in the interpretation of peritoneal cytologic specimens. Arch Pathol Lab Med; 2009 May;133(5):739-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: The presence of malignant cells in peritoneal washings leads to classification as International Federation of Gynecology and Obstetrics stage IC or higher in ovarian carcinomas and at least International Federation of Gynecology and Obstetrics stage IIIA in endometrial carcinomas.
  • Malignant cells might be few in number and might be unrecognized among a large population of mesothelial cells and/or macrophages, or reactive mesothelial cells might be misinterpreted as neoplastic cells leading to unnecessary chemotherapy.
  • OBJECTIVE: To evaluate the main pitfalls in the evaluation of peritoneal washings in patients with gynecologic malignancies and analyze the ancillary studies that might be helpful to achieve the correct diagnosis with an emphasis on immunocytochemistry.
  • [MeSH-major] Adenocarcinoma / pathology. Ascitic Fluid / pathology. Cytodiagnosis / methods. Genital Neoplasms, Female / pathology. Peritoneal Lavage
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415948.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 63
  •  go-up   go-down


18. Kodama J, Seki N, Ojima Y, Nakamura K, Hongo A, Hiramatsu Y: Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus. Eur J Obstet Gynecol Reprod Biol; 2007 Mar;131(1):76-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus.
  • OBJECTIVE: The purpose of this study was to determine the value of prognostic factors and to assess the efficacy of adjuvant chemotherapy in patients with endometrial cancer confined to the uterus.
  • STUDY DESIGN: Patients surgically stage IB, IC and II endometrial cancer according to the International Federation of Gynecology and Obstetrics were enrolled in this study.
  • Stage IIIA tumors with positive peritoneal cytology, in the absence of other evidence of extra uterine disease, were also included.
  • RESULTS: One hundred and sixty-seven patients fulfilled the eligibility criteria and 58 patients (34.7%) underwent combination chemotherapy.
  • Disease recurrence occurred in 10 patients within a median time of 17 months.
  • Fourteen of 23 patients with histologic grade 3 tumors received adjuvant chemotherapy consisting of cyclophosphamide (or etoposide), epirubicin and cisplatin (in 1989-1999) or paclitaxel, pirarubicin and carboplatin (in 2000-2002).
  • The 5-year disease-free and overall survival rates for these individuals was 92.3%, a value significantly higher than those in patients who had not undergone chemotherapy (50.0%).
  • CONCLUSIONS: Histologic grade of 3 is an independent prognostic marker in patients with endometrial cancer confined to the uterus and adjuvant chemotherapy might improve the survival rates in these patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Treatment Outcome. Uterus / pathology

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16459012.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


19. Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, Kudo R, Japanese Gynecologic Oncology Group: Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol; 2008 Jan;108(1):226-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
  • OBJECTIVE: To establish an optimal adjuvant therapy for intermediate- and high-risk endometrial cancer patients, we conducted a multi-center randomized phase III trial of adjuvant pelvic radiation therapy (PRT) versus cyclophosphamide-doxorubicin-cisplatin (CAP) chemotherapy in women with endometrioid adenocarcinoma with deeper than 50% myometrial invasion.
  • The PRT group received at least 40 Gy.
  • These rates were also not significantly different in a low- to intermediate-risk group defined as stage IC patients under 70 years old with G1/2 endometrioid adenocarcinoma.
  • However, among 120 patients in a high- to intermediate-risk group defined as (1) stage IC in patients over 70 years old or with G3 endometrioid adenocarcinoma or (2) stage II or IIIA (positive cytology), the CAP group had a significantly higher PFS rate (83.8% vs. 66.2%, log-rank test P=0.024, hazard ratio 0.44) and higher OS rate (89.7% vs. 73.6%, log-rank test P=0.006, hazard ratio 0.24).
  • CONCLUSION: Adjuvant chemotherapy may be a useful alternative to radiotherapy for intermediate-risk endometrial cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / radiotherapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Patient Compliance. Prognosis. Radiotherapy, Adjuvant. Risk Factors. Treatment Outcome


20. Small W Jr, Mahadevan A, Roland P, Vallow L, Zusag T, Fishman D, Massad S, Rademaker A, Kalapurakal JA, Chang S, Lurain J: Whole-abdominal radiation in endometrial carcinoma: an analysis of toxicity, patterns of recurrence, and survival. Cancer J; 2000 Nov-Dec;6(6):394-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-abdominal radiation in endometrial carcinoma: an analysis of toxicity, patterns of recurrence, and survival.
  • PURPOSE: The purpose of this study was to determine the toxicity, patterns of recurrence, and survival in high-risk endometrial cancer patients treated with whole-abdominal radiation.
  • MATERIALS AND METHODS: All patients with endometrial cancer treated at Northwestern University since 1994 and at Rush University since 1993 were retrospectively reviewed.
  • The mean and median follow-up was 2.3 and 2.1 years, respectively, with a range of 0.13 to 6.1 years.
  • Forty-seven percent of the patients were found to have serous histology as a component of their tumor.
  • Surgical staging results included 19% stage 1B, 4% stage IC, 8% stage IIB, 37% stage IIIA, 26% stage IIIC, and 7% stage IVB.
  • Megestrol acetate (Megace) was used as an adjuvant treatment in 37% of patients, and no cases received initial chemotherapy.
  • All patients received WAR with a mean total dose and dose per fraction of 2620 and 143 cGy, respectively.
  • CONCLUSIONS: Utilizing a conservatrive total whole-abdominal radiation dose and limited para-aortic nodal boost resulted in very tolerable treatments.
  • [MeSH-major] Abdominal Neoplasms / prevention & control. Abdominal Neoplasms / secondary. Endometrial Neoplasms / radiotherapy. Neoplasm, Residual / radiotherapy
  • [MeSH-minor] Adenocarcinoma, Papillary. Brachytherapy. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Ovariectomy. Radiotherapy Dosage. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11131490.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Yahata H, Hirakawa T, Fujita T, Ariyoshi K, Sonoda K, Amada S, Kobayashi H, Nakano H: Postoperative adjuvant chemotherapy with cisplatin, cyclophosphamide, and anthracycline (doxorubicin, epirubicin, pirarubicin) for endometrial cancer. Int J Clin Oncol; 2004 Aug;9(4):317-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative adjuvant chemotherapy with cisplatin, cyclophosphamide, and anthracycline (doxorubicin, epirubicin, pirarubicin) for endometrial cancer.
  • BACKGROUND: Doxorubicin and cisplatin are the most commonly used chemotherapeutic agents in the treatment of endometrial cancer, but their clinical efficacy is still controversial.
  • The aim of this study was to retrospectively assess the efficacy and toxicity of combination chemotherapy using cisplatin, cyclophosphamide, and anthracy-clines in patients with stage III/IV adenocarcinoma of the endometrium.
  • METHODS: Forty patients with advanced endometrial cancer received postoperative adjuvant combination chemotherapy, using cisplatin (50 or 70 mg/m2), cyclophosphamide (500 mg/m2), and one of three anthracyclines (10 patients with doxorubicin [50 mg/m2], 18 with epirubicin [50 mg/m2], and 12 with pirarubicin [40 mg/m2]), from 1987 to 1999.
  • No patients in stage IIIa (n = 10), however, had recurrence.
  • In group 2, 6 of the 13 (46%) showed response to chemotherapy (complete response [CR], 31%; partial response [PR], 15%).
  • CONCLUSION: In group 1, the survival of patients receiving chemotherapy was considered favorable, but patients with recurrent lesions had poor prognosis.
  • On the other hand, in group 2, the efficacy of the chemotherapy was almost equal to that reported in the literature; however, this regimen did not contribute to an improvement in the survival rate.
  • In conclusion, a new effective regimen of postoperative adjuvant therapy is highly desirable in patients with measurable residual lesions.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Aged. Anthracyclines / administration & dosage. Chemotherapy, Adjuvant / methods. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Female. Gynecologic Surgical Procedures / methods. Humans. Middle Aged. Neoplasm Staging. Neoplasm, Residual. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15375709.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anthracyclines; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Kim S, Wu HG, Lee HP, Kang SB, Song YS, Park NH, Ha SW: Patterns of failure after postoperative radiation therapy for endometrial carcinoma. Cancer Res Treat; 2006;38(3):133-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of failure after postoperative radiation therapy for endometrial carcinoma.
  • PURPOSE: We tried to investigate the outcome and patterns of failure of endometrial cancer patients who were treated with surgery and postoperative radiation therapy (RT).
  • MATERIALS AND METHODS: Eighty-three patients with endometrial cancer who received postoperative RT between May 1979 and August 2000 were included in this retrospective study.
  • All the patients were staged according to 1988 FIGO (International Federation of Gynecology and Obstetrics) staging system; 2 were stage IA, 23 were stage IB, 20 were stage IC, 4 were stage IIA, 5 were stage IIB, 9 were stage IIIA, 2 were stage IIIB and 18 were stage IIIC.
  • All the patients received external beam RT (EBRT) with a median dose of 5,040 cGy (range: 4,500 approximately 5,075 cGy) to the whole pelvis.
  • RESULTS: Overall, 11 patients (13%) experienced disease relapse: 4 with initial stage I or II disease and 7 with initial stage III disease.
  • Among the 54 stage I or II patients, 1 (2%) relapsed in the pelvis only, 2 (4%) relapsed in the vagina and distant organs, and 1 (2%) relapsed in the paraaortic lymph nodes (PANs).
  • Among the 29 stage III patients, 1 (3%) relapsed in the vagina.
  • The most common sites of failure for the stage III patients were the peritoneum (3 patients, 10%), PANs (2 patients, 7%), and lung (2 patients, 7%).
  • With a median follow-up period of 86 months, the overall survival (OS) and disease-free survival (DFS) rates at 5 years were 87% for both.
  • The five-year DFS rate was 93%, 100% and 74% for the stage I, II and III patients, respectively.
  • Three patients experienced severe radiation-related late complications: RTOG (Radiation Therapy Oncology Group) grade 3 radiation cystitis was seen in one patient, and grade 3 bowel obstruction was seen in two patients.
  • The major patterns of failure for stage III patients were peritoneal seeding and distant metastasis.
  • Selective use of whole abdominal radiotherapy or adjuvant chemotherapy may improve the therapeutic outcome of these patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):233-8 [11161865.001]
  • [Cites] Gynecol Oncol. 2000 Oct;79(1):79-85 [11006036.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):834-8 [15927414.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):755-63 [15913742.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):101-4 [9747826.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] Gynecol Oncol. 1995 May;57(2):138-44 [7729725.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1992 Nov;4(6):373-6 [1463690.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(5):905-11 [1555983.001]
  • [Cites] Gynecol Oncol. 1989 Apr;33(1):68-70 [2703169.001]
  • [Cites] J Natl Cancer Inst. 1988 Apr 20;80(4):276-8 [3280811.001]
  • [Cites] Radiobiol Radiother (Berl). 1987;28(4):519-28 [3685293.001]
  • [Cites] Obstet Gynecol. 1980 Oct;56(4):419-27 [6999399.001]
  • [Cites] Cancer Treat Rep. 1979 Jan;63(1):21-7 [369691.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73 [15093913.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] Gynecol Oncol. 2003 May;89(2):236-42 [12713986.001]
  • [Cites] Gynecol Oncol. 2002 Dec;87(3):274-80 [12468325.001]
  • [Cites] Gynecol Oncol. 2002 Mar;84(3):437-42 [11855884.001]
  • (PMID = 19771273.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2741680
  • [Keywords] NOTNLM ; Endometrial neoplasms / Patterns of failure / Postoperative radiation therapy
  •  go-up   go-down


23. Bakrin N, Cotte E, Sayag-Beaujard A, Raudrant D, Isaac S, Mohamed F, Gilly FN, Glehen O: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of recurrent endometrial carcinoma confined to the peritoneal cavity. Int J Gynecol Cancer; 2010 Jul;20(5):809-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of recurrent endometrial carcinoma confined to the peritoneal cavity.
  • Our objective was to determine if cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a feasible therapeutic option for treatment of peritoneal recurrence of endometrial carcinoma.
  • Between August 2002 and May 2007, 5 patients with recurrent endometrial carcinoma confined to the peritoneal cavity who underwent CRS with HIPEC.
  • Of the 5 patients treated, histopathological type and International Federation of Gynecology and Obstetrics stage were as follows: IB endometrioid (n = 1), IIIA endometrioid (n = 1), IIIC endometrioid (n = 2), and IC endometrioid + pseudosarcomatoid component (n = 1).
  • One patient with pseudosarcomatoid component developed recurrent disease 10 months after surgery and died 2 months later.
  • One patient experienced early recurrence with a malignant pleural effusion and died.
  • Regarding the toxicity of the procedure, highly selected patients with recurrent endometrial carcinoma confined to the peritoneal cavity may benefit from improved survival after CRS with HIPEC.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Endometrial Neoplasms / therapy. Neoplasm Recurrence, Local / therapy. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Female. Gynecologic Surgical Procedures. Humans. Hyperthermia, Induced. Infusions, Parenteral. Middle Aged. Mitomycin / administration & dosage

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973274.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


24. Wethington SL, Barrena Medel NI, Wright JD, Herzog TJ: Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery. Gynecol Oncol; 2009 Oct;115(1):18-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance and treatment implications of positive peritoneal cytology in endometrial adenocarcinoma: Unraveling a mystery.
  • OBJECTIVE: Review the literature on positive peritoneal cytology in endometrioid endometrial adenocarcinoma, its prognostic value, proposed treatment strategies, and future avenues of investigation.
  • METHODS: PubMed search of articles pertaining to stage IIIA endometrioid endometrial adenocarcinoma identified over 50 articles that were reviewed.
  • Low-risk stage IIIA1 was defined as those with grade 1 or 2 disease, no evidence of cervical involvement, myometrial invasion less than 50% and no lymph vascular space invasion (LVSI).
  • In low-risk stage IIIA1 endometrial carcinoma patients, the rate of recurrence is 4.1%.
  • In contrast, in high-risk stage IIIA1 endometrial carcinoma patients the rate of recurrence is 32%, a statistically significant difference (p<0.001).
  • CONCLUSIONS: To date there is no definitive consensus on the prognostic significance of positive peritoneal cytology alone.
  • However, even in the low-risk cohort with stage IIIA1 some patients will recur.
  • Adjuvant therapy for low-risk stage IIIA diseased may or may not be of benefit.
  • High-risk disease should be treated with chemotherapy, radiation or a combination thereof.
  • A prospective, multicenter trial of comprehensively surgically staged patients with stage IIIA endometrial cancer is indicated in order to clearly define prognosis and treatment for these patients.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / therapy. Peritoneal Cavity / pathology
  • [MeSH-minor] Female. Humans. Neoplasm Staging. Prognosis. Risk Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632708.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Mangili G, De Marzi P, Beatrice S, Rabaiotti E, Viganò R, Frigerio L, Gentile C, Fazio F: Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings. BMC Cancer; 2006;6:198
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings.
  • BACKGROUND: There is still much debate about the best adjuvant therapy after surgery for endometrial cancer (EC) and there are no current guidelines.
  • METHODS: Twenty-three patients with high-risk EC (stage IIB, IIIA, IIIC or IC G3 without lymphadenectomy or with aneuploid tumor) underwent primary surgery and were then referred for adjuvant therapy.
  • P was given at a dose of 60 mg/m2 once weekly for five weeks during RT, which consisted of a total radiation dose of 50.4 Gy.
  • Overall survival and disease-free survival were calculated from the time of surgery.
  • RESULTS: A total of 157 cycles of P were administered both during radiotherapy and consolidation chemotherapy.
  • Median time to recurrence was 18.6 months (range 3-28).
  • In this group median time to recurrence was 19.2 months (range 3-28).
  • CONCLUSION: This small series demonstrates pelvic radiotherapy in combination with weakly P followed by three consolidation chemotherapy cycles as an effective combined approach in high risk endometrial carcinoma patients.
  • [MeSH-major] Chemotherapy, Adjuvant / methods. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / radiotherapy. Paclitaxel / therapeutic use. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Aged. Disease-Free Survival. Female. Humans. Middle Aged. Pilot Projects. Ploidies. Radiation Dosage. Recurrence. Risk Factors. Treatment Failure

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Radiat Oncol. 2000 Jan;10(1):23-8 [10671655.001]
  • [Cites] Cell Motil Cytoskeleton. 2000 Mar;45(3):223-34 [10706777.001]
  • [Cites] Lancet. 2000 Apr 22;355(9213):1404-11 [10791524.001]
  • [Cites] Gynecol Obstet Invest. 2000;50(2):127-32 [10965198.001]
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):53-7 [11277649.001]
  • [Cites] J Epidemiol Biostat. 2001;6(1):47-86 [11385776.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1145-53 [11483323.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4048-53 [11600606.001]
  • [Cites] J Reprod Med. 2002 Mar;47(3):173-89; discussion 189-90 [11933681.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(3):216-20 [12094958.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):537-46 [13678721.001]
  • [Cites] Cancer Invest. 2003;21(6):887-96 [14735693.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6D):5191-6 [14981988.001]
  • [Cites] Gynecol Oncol. 2004 Mar;92(3):744-51 [14984936.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):168-73 [15093913.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):345-52 [15099944.001]
  • [Cites] Histopathology. 2004 Jun;44(6):603-14 [15186276.001]
  • [Cites] Cancer Treat Rep. 1979 Jan;63(1):21-7 [369691.001]
  • [Cites] Obstet Gynecol. 1980 Oct;56(4):419-27 [6999399.001]
  • [Cites] Obstet Gynecol. 1982 Feb;59(2):225-8 [7043339.001]
  • [Cites] Gynecol Oncol. 1990 Feb;36(2):166-71 [2298404.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):305-8 [2227540.001]
  • [Cites] Gynecol Oncol. 1991 Jan;40(1):55-65 [1989916.001]
  • [Cites] Am J Obstet Gynecol. 1994 Jun;170(6):1677-81; discussion 1681-2 [8203425.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2682-6 [7989944.001]
  • [Cites] Gynecol Oncol. 1995 May;57(2):138-44 [7729725.001]
  • [Cites] Nihon Sanka Fujinka Gakkai Zasshi. 1996 Jan;48(1):45-51 [8576621.001]
  • [Cites] Anticancer Drugs. 1996 Feb;7(2):182-8 [8740723.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):278-81 [8751561.001]
  • [Cites] Clin Obstet Gynecol. 1996 Sep;39(3):716-27 [8862895.001]
  • [Cites] Gynecol Oncol. 1996 Oct;63(1):34-9 [8898165.001]
  • [Cites] Ann Oncol. 1996 Oct;7(8):861-3 [8922203.001]
  • [Cites] Semin Oncol. 1996 Dec;23(6 Suppl 16):108-12 [9007135.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):885-95 [9128966.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):755-63 [15913742.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):36-44 [16330675.001]
  • [Cites] Am J Clin Oncol. 1996 Jun;19(3):290-1 [8638543.001]
  • (PMID = 16869961.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC1559635
  •  go-up   go-down


26. Lupe K, Kwon J, D'Souza D, Gawlik C, Stitt L, Whiston F, Nascu P, Wong E, Carey MS: Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach. Int J Radiat Oncol Biol Phys; 2007 Jan 1;67(1):110-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach.
  • PURPOSE: To determine the feasibility of adjuvant paclitaxel and carboplatin chemotherapy interposed with involved field radiotherapy for women with advanced endometrial cancer.
  • METHODS AND MATERIALS: This was a prospective cohort study of women with Stage III and IV endometrial cancer.
  • Adjuvant therapy consisted of 4 cycles of paclitaxel (175 mg/m(2)) and carboplatin (350 mg/m(2)) every 3 weeks, followed sequentially by external beam radiotherapy (RT) to the pelvis (45 Gy), followed by an additional two cycles of chemotherapy.
  • RESULTS: Thirty-three patients (median age, 63 years) received treatment between April 2002 and June 2005.
  • Stage distribution was as follows: IIIA (21%), IIIC (70%), IVB (9%).
  • Combination chemotherapy was successfully administered to 30 patients (91%) and 25 patients (76%), before and after RT respectively.
  • Nine patients (27%) experienced acute Grade 3 or 4 chemotherapy toxicities.
  • Six (18%) patients developed chronic RT toxicity.
  • There were no treatment-related deaths.
  • CONCLUSIONS: Adjuvant treatment with combination chemotherapy interposed with involved field radiation in advanced endometrial cancer was well tolerated.
  • This protocol may be suitable for further evaluation in a clinical trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / radiotherapy
  • [MeSH-minor] Acute Disease. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carboplatin / adverse effects. Chemotherapy, Adjuvant / adverse effects. Drug Administration Schedule. Feasibility Studies. Female. Humans. Hysterectomy. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Prospective Studies. Radiation Injuries / etiology. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084542.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


27. Kim HS, Kim JW, Wu HG, Chung HH, Park NH, Song YS, Kang SB, Lee HP: Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience. J Obstet Gynaecol Res; 2010 Jun;36(3):598-604
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.
  • AIM: We sought to compare survival and toxicity between paclitaxel/carboplatin (TC) and doxorubicin/cisplatin (AP) for concurrent chemoradiation (CCR) in intermediate- or high-risk endometrioid endometrial cancer.
  • METHODS: The clinical data of 40 patients with intermediate- (FIGO stage IC-IIB, n = 12) or high-risk endometrioid endometrial cancer (FIGO stage IIIA-IVA, n = 28) were reviewed retrospectively between March 2000 and December 2007, who were treated with TC (n = 23, group 1) or AP (n = 17, group 2) for CCR after surgery.
  • However, >or=6 cycles of chemotherapy improved PFS compared with 3-5 cycles of chemotherapy (51 vs 21 months, P = 0.04), suggesting that >or=6 cycles of chemotherapy was an independent prognostic factor improving PFS (adjusted HR, 0.27; 95% CI, 0.08 to 0.91; P = 0.04).
  • Grade 3 or 4 hematological and non-hematological, especially, gastrointestinal, toxicities related with chemotherapy during CCR were more common in group 2 than in group 1, whereas there was no difference in grade 3 or 4 late complication by CCR between the 2 groups.
  • CONCLUSION: These findings suggest that TC may have comparable efficacy to AP for CCR with lesser toxicity, and >or=6 cycles of chemotherapy may be more beneficial than 3-5 cycles of chemotherapy in intermediate- or high-risk endometrioid endometrial cancer.
  • [MeSH-major] Carboplatin / therapeutic use. Carcinoma, Endometrioid / drug therapy. Cisplatin / therapeutic use. Doxorubicin / therapeutic use. Endometrial Neoplasms / drug therapy. Paclitaxel / therapeutic use
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Databases, Factual. Disease-Free Survival. Female. Humans. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Statistics, Nonparametric. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20598043.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Ferrandina G, Zannoni GF, Martinelli E, Vellone V, Prisco MG, Scambia G: Endometrial carcinoma recurring as carcinosarcoma: report of two cases. Pathol Res Pract; 2007;203(9):677-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial carcinoma recurring as carcinosarcoma: report of two cases.
  • Endometrial carcinosarcoma is a rare, aggressive disease, accounting for approximately 3% of all uterine neoplasms.
  • The emergence of sarcomatous elements is considered the evolution of subclones arising from high grade endometrial carcinomas.
  • Here, we report two cases of primary endometrial carcinomas recurring as carcinosarcoma.
  • Case 1. a 58-year-old postmenopausal woman diagnosed to have a poorly differentiated endometrial endometrioid adenocarcinoma (FIGO stage IB) developed an intra-abdominal recurrence of disease after 17 months from diagnosis.
  • Histopathological analysis documented a biphasic neoplasia consisting of an epithelial (grade 3 endometrial endometrioid adenocarcinoma) and a sarcomatous component.
  • Salvage chemotherapy with cisplatin, ifosfamide, epirubicin, and then with taxotere was attempted.
  • The patient died after 2 months. Case 2.
  • A 56-year-old woman with a diagnosis of grade 3 endometrial adenosquamous carcinoma of the endometrium (FIGO stage IIIA) experienced pelvic recurrence after five months from completion of chemotherapy.
  • Definitive histology was malignant mixed mesodermal tumor with focal areas of chondrosarcomatous elements.
  • The patient was triaged to exclusive concomitant chemoradiotherapy and salvage chemotherapy.
  • We describe two cases of high grade endometrial carcinomas recurring as carcinosarcoma, thus providing evidence that the metaplastic sarcomatous evolution is a very rare event which can occur in patients with anaplastic endometrial cancer.
  • [MeSH-major] Carcinoma, Adenosquamous / pathology. Carcinoma, Endometrioid / secondary. Carcinosarcoma / secondary. Chondrosarcoma / secondary. Endometrial Neoplasms / pathology. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Differentiation. Combined Modality Therapy. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Salvage Therapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646054.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


29. Kelly MG, O'Malley D, Hui P, McAlpine J, Dziura J, Rutherford TJ, Azodi M, Chambers SK, Schwartz PE: Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecol Oncol; 2004 Dec;95(3):469-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.
  • OBJECTIVE: The coexistence of minimal uterine disease and extrauterine metastases is common in patients with uterine papillary serous carcinoma (UPSC).
  • The purpose of this study was to evaluate different therapeutic options in surgically staged patients.
  • METHODS: We retrospectively reviewed all patients with UPSC histologically limited in the uterus to the endometrium treated at our institution between 1987 and 2002.
  • RESULTS: Twenty-three (45%) cases were International Federation of Gynecology and Obstetrics (FIGO) stage IA, seven (15%) were stage IIIA, one (2%) was stage IIIC, and nine (18%) stage IV.
  • Additionally, 11 of these 51 patients (21%) were diagnosed with two cancers: a stage IA UPSC and concomitant advanced stage serous cancer of the ovary, fallopian tube, or peritoneum.
  • Stage IA patients with no cancer in the hysterectomy specimen (defined as no residual uterine disease) had no recurrences (n = 10) regardless of treatment.
  • There was a trend toward increased survival in stage IA patients with residual uterine disease who were treated with chemoradiation (concomitant vaginal brachytherapy and platinum-based chemotherapy).
  • There were no recurrences in patients with locoregional disease (stages IA-IIIA) who received chemoradiation.
  • All patients with advanced stage UPSC (stage IIIC or IV or two primary cancers) did poorly regardless of treatment.
  • CONCLUSION: Our findings suggest that stage IA patients with no residual uterine disease may be observed.
  • Stage IA patients with residual uterine disease may benefit from chemoradiation.
  • More effective treatment needs to be identified for advanced stage UPSC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cystadenocarcinoma, Papillary / therapy. Cystadenocarcinoma, Serous / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Brachytherapy. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15581948.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin
  •  go-up   go-down






Advertisement